L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous?
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: L-Arginine is the precursor for nitric oxide synthesis. In the brain, nitric oxide acts as a neurotransmitter; in the immune system, nitric oxide acts as a mediator of host defense; in the cardiovascular system, nitric oxide mediates the protective effects of the intact endothelium, acting as an endogenous antiatherogenic molecule. RECENT FINDINGS: About 5 g of L-arginine is taken up each day. L-Arginine plasma levels are not significantly reduced in most diseases, except end-stage renal failure during hemodialysis treatment. Nonetheless, intravenous or oral administration of L-arginine results in enhanced nitric oxide elaboration in subjects with impaired endothelial function. In clinical trials short to medium-term administration of L-arginine improved the symptoms of cardiovascular disease. In other trials, however, L-arginine was not beneficial and in one recent long-term study higher mortality of subjects receiving L-arginine than those receiving placebo was reported. These contradictory results were not understood for a long time. The endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine, may determine a subject's response to L-arginine. L-Arginine appears to exert no effect in subjects with low asymmetric dimethylarginine levels, whereas in subjects with high asymmetric dimethylarginine levels L-arginine restores the L-arginine/asymmetric dimethylarginine ratio to normal and normalizes endothelial function. SUMMARY: The effects of L-arginine supplementation on human physiology appear to be multicausal and dose related. Criteria need to be developed to define patients who benefit from L-arginine supplementation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arginine metabolism: nitric oxide and beyond
WU, G., & MORRIS, S. M. (1998) · Biochemical Journal · doi:10.1042/bj3360001 · Cited by 2,811
Berkowitz, D. E., White, R., Li, D., Minhas, K. M., Cernetich, A., Kim, S., Burke, S., Shoukas, A. A., Nyhan, D., Champion, H. C., et al. (2003) · Circulation · doi:10.1161/01.cir.0000092948.04444.c7 · Cited by 486
Xu, W., Kaneko, F. T., Zheng, S., Comhair, S. A. A., Janocha, A. J., Goggans, T., Thunnissen, F. B. J. M., Farver, C., Hazen, S. L., Jennings, C., et al. (2004) · The FASEB Journal · doi:10.1096/fj.04-2317fje · Cited by 369
Schulman, S. P., Becker, L. C., Kass, D. A., Champion, H. C., Terrin, M. L., Forman, S., Ernst, K. V., Kelemen, M. D., Townsend, S. N., Capriotti, A., et al. (2006) · JAMA · doi:10.1001/jama.295.1.58 · Cited by 357
l -Arginine Supplementation in Peripheral Arterial Disease: No Benefit and Possible Harm
Wilson, A. M., Harada, R., Nair, N., Balasubramanian, N., & Cooke, J. P. (2007) · Circulation · doi:10.1161/circulationaha.106.683656 · Cited by 241
Cited by
The Effect of Nitric-Oxide-Related Supplements on Human Performance
Bescós, R., Sureda, A., Tur, J. A., & Pons, A. (2012) · Sports Medicine · doi:10.2165/11596860-000000000-00000 · Cited by 231
Alef, M. J., Vallabhaneni, R., Carchman, E., Morris, S. M., Shiva, S., Wang, Y., Kelley, E. E., Tarpey, M. M., Gladwin, M. T., Tzeng, E., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44079 · Cited by 101
Suliburska, J., Bogdanski, P., Szulinska, M., Pupek-Musialik, D., & Jablecka, A. (2014) · European Journal of Nutrition · doi:10.1007/s00394-013-0533-7 · Cited by 47
Nitric oxide and nitrite-based therapeutic opportunities in intimal hyperplasia
Alef, M. J., Tzeng, E., & Zuckerbraun, B. S. (2012) · Nitric Oxide · doi:10.1016/j.niox.2012.03.014 · Cited by 20
Metadata
- Authors
- Böger, R. H.
- Venue
- Current Opinion in Clinical Nutrition and Metabolic Care
- Published
- 2008-01
- Volume
- 11
- Issue
- 1
- Pages
- 55-61
- ISSN
- 1363-1950 (ISSN-L)
- OpenAlex
- W2010799584
- Cited by
- 77
- References
- 5
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous? https://app.cochat.ai/papers/10.1097/mco.0b013e3282f2b0c3
- The paper
- Böger, R. H. (2008). L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous? Current Opinion in Clinical Nutrition and Metabolic Care. https://doi.org/10.1097/mco.0b013e3282f2b0c3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.